Axon Enterprise (AXON) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	TASER INTERNATIONAL INC
Entity Central Index Key	1069183
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		53,450,185

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$46,848	$48,367
Short-term investments	43,212	32,774
Accounts and notes receivable, net of allowance of $200 and $251 as of March 31, 2015 and December 31, 2014, respectively	21,022	30,735
Inventory, net	22,626	18,323
Prepaid expenses and other current assets	4,276	4,443
Deferred income tax assets, net	5,186	5,186
Total current assets	143,170	139,828
Property and equipment, net of accumulated depreciation of $34,338 and $33,906 as of March 31, 2015 and December 31, 2014, respectively	17,213	17,523
Deferred income tax assets, net	11,505	10,877
Intangible assets, net	2,965	3,115
Goodwill	2,206	2,206
Long-term investments	14,713	9,296
Other assets	4,039	2,523
Total assets	195,811	185,368
Current liabilities:
Accounts payable	7,808	7,682
Accrued liabilities	6,999	9,245
Current portion of deferred revenue	14,628	14,020
Customer deposits	647	988
Current portion of capital lease payable	39	38
Total current liabilities	30,121	31,973
Deferred revenue, net of current portion	22,443	21,668
Liability for unrecognized tax benefits	1,645	1,471
Long-term deferred compensation	1,549	1,121
Long-term portion of capital lease payable	19	29
Total liabilities	55,777	56,262
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2015 and December 31, 2014	0	0
Common stock, $0.00001 par value; 200,000,000 shares authorized; 53,359,345 and 53,000,867 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	1	1
Additional paid-in capital	166,275	162,641
Treasury stock at cost, 18,139,958 shares as of March 31, 2015 and December 31, 2014	-114,645	-114,645
Retained earnings	88,250	81,045
Accumulated other comprehensive income	153	64
Total stockholders’ equity	140,034	129,106
Total liabilities and stockholders’ equity	$195,811	$185,368

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$200	$251
Accumulated depreciation	$34,338	$33,906
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	53,359,345	53,000,867
Common stock, shares outstanding	53,359,345	53,000,867
Treasury stock, shares	18,139,958	18,139,958

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net sales	$44,762	$36,185
Cost of products sold and services delivered	14,894	13,977
Gross margin	29,868	22,208
Operating expenses:
Sales, general and administrative	14,565	13,746
Research and development	4,558	3,606
Total operating expenses	19,123	17,352
Income from operations	10,745	4,856
Interest and other (expense) income, net	-65	30
Income before provision for income taxes	10,680	4,886
Provision for income taxes	3,475	1,495
Net income	7,205	3,391
Net income per common and common equivalent shares:
Basic (in dollars per share)	$0.14	$0.06
Diluted (in dollars per share)	$0.13	$0.06
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	53,167	53,190
Diluted (in shares)	54,513	55,124
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	7,205	3,391
Foreign currency translation adjustments	89	10
Comprehensive income	$7,294	$3,401

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$7,205	$3,391
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	617	1,162
Loss on write-down / disposal of property and equipment, net	0	15
Loss on disposal of intangibles	139	80
Bond premium amortization	379	192
Provision for doubtful accounts	44	1
Provision for excess and obsolete inventory	181	7
(Recovery of) provision for warranty expense	-34	306
Stock-based compensation	1,544	1,177
Deferred income taxes	-471	6,401
Unrecognized tax benefits	174	-1,285
Excess tax benefit from stock-based compensation	-1,679	-4,723
Change in assets and liabilities:
Accounts and notes receivable	9,669	1,986
Inventory	-4,484	-2,150
Prepaid expenses and other assets	-1,399	-4,574
Accounts payable, accrued and other liabilities	81	1,628
Deferred revenue	1,383	1,307
Customer deposits	-341	-611
Net cash provided by operating activities	13,008	4,310
Cash flows from investing activities:
Purchases of investments	-26,863	-13,822
Proceeds from call / maturity of investments	10,629	2,380
Purchases of property and equipment	-424	-799
Purchases of intangible assets	-50	-67
Net cash used in investing activities	-16,708	-12,308
Cash flows from financing activities:
Proceeds from options exercised	605	7,275
Payroll tax payments for net-settled stock awards	-194	-1,138
Payments on capital lease obligation	-9	-8
Excess tax benefit from stock-based compensation	1,679	4,723
Net cash provided by financing activities	2,081	10,852
Effect of exchange rate changes on cash and cash equivalents	100	8
Net (decrease) increase in cash and cash equivalents	-1,519	2,862
Cash and cash equivalents, beginning of period	48,367	42,271
Cash and cash equivalents, end of period	46,848	45,133
Supplemental disclosure:
Cash paid for income taxes, net	209	50
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	$42	$114

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies
	TASER International, Inc. (“TASER” or the “Company”) is a developer and manufacturer of advanced conducted electrical weapons (“CEWs”) designed for use by law enforcement, military, corrections, and private security personnel and by private individuals for personal defense. In addition, the Company has developed full technology solutions for the capture, storage and management of video/audio evidence as well as other tactical capabilities for use in law enforcement. The Company sells its products worldwide through its direct sales force, distribution partners, online store and third-party resellers. The Company was incorporated in Arizona in September 1993, and reincorporated in Delaware in January 2001. The Company’s corporate headquarters and manufacturing facilities are located in Scottsdale, Arizona. The Company’s software development unit facility is located in Seattle, Washington.
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries, including TASER International Europe SE (“TASER Europe”). TASER Europe was established in 2009 to facilitate sales and provide customer service to our customers in the European region. In 2014, the Company established TASER International, B.V. located in Amsterdam, the Netherlands, that will serve as its international headquarters. All material intercompany accounts, transactions, and profits have been eliminated.
	a. Basis of Presentation and Use of Estimates
	These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:
	•	product warranty reserves,
	•	inventory valuation reserves,
	•	accounts receivable reserves,
	•	revenue recognition allocated in multiple-deliverable contracts or arrangements,
	•	valuation of goodwill, intangibles and long-lived assets,
	•	recognition, measurement and valuation of current and deferred income taxes,
	•	projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense,
	•	fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and
	•	recognition and measurement of contingencies and accrued litigation expense.
	Actual results could differ materially from those estimates.
	b. Segment Information
	The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, AXON camera products and EVIDENCE.com (the “AXON” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13.
	c. Geographic Information and Major Customers
	For the three months ended March 31, 2015 and 2014, net sales by geographic area were as follows (in thousands):
		Three Months Ended March 31,
		2015						2014
	United States	$	35,501		79.3	%		$	25,576	70.7	%
	Other Countries	9,261			20.7			10,609		29.3
	Total	$	44,762		100	%		$	36,185	100	%
	Sales to customers outside of the U.S. are typically denominated in U.S. dollars and are attributed to each country based on the shipping address of the distributor or customer. For the three months ended March 31, 2015 or 2014, no individual country outside the U.S. represented more than 10% of net sales. Sales in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of the Company's customers.
	The Company sells its products primarily through a network of unaffiliated distributors. The Company also reserves the right to sell directly to the end user to secure the customer’s account. For the three months ended March 31, 2015 and 2014, no customer represented more than 10% of total net sales. At March 31, 2015 and December 31, 2014, the Company had a trade receivable from one unaffiliated customer comprising 10.1% and 13.4%, respectively, of the aggregate accounts receivable balance.
	d. Income per Common Share
	Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):
		Three Months Ended March 31,
		2015			2014
	Numerator for basic and diluted earnings per share:
	Net income	$	7,205		$	3,391
	Denominator:
	Weighted average shares outstanding—basic	53,167			53,190
	Dilutive effect of stock-based awards	1,346			1,934
	Diluted weighted average shares outstanding	54,513			55,124
	Anti-dilutive stock-based awards excluded	362			315
	Net income per common share:
	Basic	$	0.14		$	0.06
	Diluted	$	0.13		$	0.06
	e. Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable
	The Company derives revenue from two primary sources: (1) the sale of physical products, including our CEWs, AXON cameras, corresponding extended warranties, and related accessories such as cartridges and batteries, and (2) subscription to the Company's EVIDENCE.com SaaS (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract.
	Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price.
	The Company offers the right to purchase extended warranties that include additional services and coverage beyond the limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years.
	EVIDENCE.com and AXON cameras are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of EVIDENCE.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. AXON equipment has stand-alone value and represents a deliverable that is provided to the customer at the time of sale, while EVIDENCE.com services are provided over the specified term of the contract. The Company recognizes revenue for the AXON equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for EVIDENCE.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with EVIDENCE.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the allocation of arrangement consideration, part of the revenue for the equipment may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner.
	In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period.
	The Company recently launched the Officer Safety Plan (“OSP”) whereby a customer enters into a 5 year EVIDENCE.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of the AXON devices every 2.5 years, and includes a TASER CEW device at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the AXON and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of AXON devices at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered.
	Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training revenue is recorded as the service is provided.
	Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about of the Company’s deferred revenue.
	Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates and is based on their judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions.
	The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes. There were no outstanding balances related to such arrangements as of March 31, 2015 or December 31, 2014.
	f. Standard Warranties
	The Company warranties its CEWs, AXON cameras and E-Docks from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets.
	Changes in the Company’s estimated product warranty liabilities are as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance, beginning of period	$	675		$	955
	Utilization of accrual	(118		)	(174		)
	Warranty (recovery) expense	(34		)	306
	Balance, end of period	$	523		$	1,087
	g. Fair Value of Financial Instruments
	The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:
	•	Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.
	•	Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.
•	Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability.
The Company has cash equivalents and investments, which at March 31, 2015 and December 31, 2014, were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of March 31, 2015 and December 31, 2014 was $1.5 million and $1.1 million, respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.
The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets.
h. Valuation of Goodwill, Intangibles and Long-lived Assets
Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. The Company recorded losses on disposal of intangible assets of $0.1 million during each of the three months ended March 31, 2015 and 2014.
i. Recently Issued Accounting Guidance
In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (i) prospectively to all awards granted or modified after the effective date; or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time.
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, ASU 2014-09 provides for the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification Topic No. 605, “Revenue Recognition,” most industry-specific guidance throughout the industry topics of the Accounting Standards Codification, and some cost guidance related to construction-type and production-type contracts. ASU 2014-09 is effective for public entities for annual periods and interim periods within those annual periods beginning after December 15, 2016. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements.
j. Reclassification of Prior Year Presentation
Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Cash_Cash_Equivalents_and_Inve

Cash, Cash Equivalents and Investments	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments
	The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at March 31, 2015 and December 31, 2014 (in thousands):
		As of March 31, 2015
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-Term Investments		Long-Term Investments
	Cash	$	44,113	$	—	$	—		$	44,113	$	44,113	$	—	$	—
	Level 1:
	Money market funds	2,054		—		—			2,054		2,054		—		—
	Corporate bonds	36,548		—		(54		)	36,494		—		26,162		10,386
	Subtotal	38,602		—		(54		)	38,548		2,054		26,162		10,386
	Level 2:
	State and municipal obligations	19,108		13		—			19,121		681		15,580		2,847
	Certificates of deposit	2,950		—		—			2,950		—		1,470		1,480
	Subtotal	22,058		13		—			22,071		681		17,050		4,327
	Total	$	104,773	$	13	$	(54	)	$	104,732	$	46,848	$	43,212	$	14,713
		As of December 31, 2014
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-Term Investments		Long-Term Investments
	Cash	$	44,260	$	—	$	—		$	44,260	$	44,260	$	—	$	—
	Level 1:
	Money market funds	3,932		—		—			3,932		3,932		—		—
	Corporate bonds	20,388		—		(34		)	20,354		—		15,656		4,732
	Subtotal	24,320		—		(34		)	24,286		3,932		15,656		4,732
	Level 2:
	State and municipal obligations	19,145		18		—			19,163		175		15,891		3,079
	Certificates of deposit	2,712		—		—			2,712		—		1,227		1,485
	Subtotal	21,857		18		—			21,875		175		17,118		4,564
	Total	$	90,437	$	18	$	(34	)	$	90,421	$	48,367	$	32,774	$	9,296
	The Company believes the unrealized losses on the Company’s investments are due to interest rate fluctuations. As these investments are either short-term in nature, are expected to be redeemed at par value, and/or because the Company has the ability and intent to hold these investments to maturity, the Company does not consider these investments to be other than temporarily impaired at March 31, 2015. None of Company’s investments have been in an unrealized loss position for more than one year.
	The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at March 31, 2015 by contractual maturity (in thousands):
		Amortized Cost		Fair Value
	Due in less than one year	$	43,212	$	43,190
	Due after one year, through two years	14,713		14,694
	Due after two years	—		—
	Total short-term and long-term investments	$	57,925	$	57,884

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory
	Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. Inventories consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015			2014
	Raw materials	$	13,678		$	12,229
	Work-in-process	128			111
	Finished goods	10,416			7,337
	Reserve for excess and obsolete inventory	(1,596		)	(1,354		)
	Total inventory	$	22,626		$	18,323

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	The balance of goodwill at March 31, 2015 and December 31, 2014 was $2.2 million.
	Intangible assets (other than goodwill) consisted of the following (in thousands):
				March 31, 2015							December 31, 2014
		Useful		Gross		Accumulated			Net		Gross		Accumulated			Net
		Life		Carrying		Amortization			Carrying		Carrying		Amortization			Carrying
				Amount					Amount		Amount					Amount
	Amortized:
	Domain names	5 years		$	125	$	(117	)	$	8	$	125	$	(114	)	$	11
	Issued patents	4-15 years		1,799		(584		)	1,215		1,759		(549		)	1,210
	Issued trademarks	9-11 years		575		(211		)	364		566		(205		)	361
	Total amortized			2,499		(912		)	1,587		2,450		(868		)	1,582
	Not amortized:
	TASER trademark			900					900		900					900
	Patents and trademarks pending			478					478		633					633
	Total not amortized			1,378					1,378		1,533					1,533
	Total intangible assets			$	3,877	$	(912	)	$	2,965	$	3,983	$	(868	)	$	3,115
	Amortization expense relative to intangible assets for the three months ended March 31, 2015 and 2014 was $61,000 and $40,000, respectively. Estimated amortization for intangible assets with definitive lives for the remaining nine months of 2015, the next five years ended December 31, and thereafter, is as follows (in thousands):
	2015 (remaining nine months)	$	136
	2016	176
	2017	172
	2018	162
	2019	152
	2020	282
	Thereafter	507
	Total	$	1,587

Deferred_Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue
	Deferred revenue consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015		2014
	Warranty	$	21,701	$	21,973
	AXON services	9,055		9,286
	Hardware equipment	5,988		4,252
	Other	327		177
	Total deferred revenue	37,071		35,688
	Total current portion of deferred revenue	14,628		14,020
	Total long-term portion of deferred revenue	$	22,443	$	21,668
	The current portion of deferred revenue consists primarily of approximately $5.5 million related to AXON related services, $7.3 million related to warranties and $1.6 million related to deferred hardware. For more information relating to the Company’s revenue recognition policies please refer to Note 1(e).

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities
	Accrued liabilities consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015		2014
	Accrued salaries and benefits	$	2,144	$	3,699
	Accrued judgments and settlements	80		108
	Accrued professional fees	204		257
	Accrued warranty expense	523		675
	Accrued income and other taxes	1,893		539
	Other accrued expenses	2,155		3,967
	Accrued liabilities	$	6,999	$	9,245

Commitments_and_Contingencies

Commitments and Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Product Litigation

The Company is currently named as a defendant in 12 lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CEW was used (or present) by law enforcement officers in connection with arrests or during training exercises. In addition, two other product litigation matters in which the Company is involved are currently on appeal. While the facts vary from case to case, the product liability claims are typically based on an alleged product defect resulting in injury or death, usually involving a failure to warn, and the plaintiffs are seeking monetary damages. The information throughout this note is current through the filing date of this Quarterly Report on Form 10-Q.

As a general rule, it is the Company’s policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to the Company. Also, on occasion, the Company’s insurance company has settled such lawsuits over the Company’s objection where the risk is over the Company’s liability insurance deductibles. Due to the confidentiality of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, the Company does not identify or comment on which specific lawsuits have been settled or the amount of any settlement.

In 2009, the Company implemented new risk management strategies, including revisions to product warnings and training to better protect both the Company and its customers from litigation based on ‘failure to warn’ theories – which comprise the vast majority of the cases against the Company. These risk management strategies have been highly effective in reducing the rate and exposure from litigation post-2009. From the third quarter of 2011 to the first quarter of 2015, product liability cases have been reduced from 55 active to 12 active cases.

Management believes that pre-2009 cases have a different risk profile than cases which have occurred since the risk management procedures were introduced in 2009. Therefore, the Company necessarily treats certain pre-2009 cases as exceptions to the Company’s general no settlement policy in order to reduce caseload, legal costs and liability exposure. The Company intends to continue its successful practice of aggressively defending and generally not settling litigation except in very limited and unusual circumstances as described above.

With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter.

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Koon

8-Dec

17th Judicial Circuit Court, Broward County, FL

Training Injury

Discovery Phase

Derbyshire

9-Nov

Ontario, Canada Superior Court of Justice

Officer Injury

Discovery Phase

Thompson

10-Mar

11th Judicial Circuit Court, Miami-Dade County, FL

Suspect Injury During Arrest

Pleading Phase

Doan

10-Apr

The Queen's Bench Alberta, Red Deer Judicial Dist.

Wrongful Death

Discovery Phase

Shymko

10-Dec

The Queen's Bench, Winnipeg Centre, Manitoba

Wrongful Death

Pleading Phase

Ramsey

12-Jan

17th Judicial Circuit Court, Broward County, FL

Wrongful Death

Discovery Phase

Firman

12-Apr

Ontario, Canada Superior Court of Justice

Wrongful Death

Pleading Phase

Ricks

12-May

US District Court, WD LA

Wrongful Death

Motion Phase, trial scheduled June 2015

Schrock

14-Sep

San Bernardino County Superior Court, CA

Wrongful Death

Pleading Phase

Moore

14-Nov

St. Louis County Circuit Court, MO

Wrongful Death

Pleading Phase

Jones

15-Jan

Los Angeles County Superior Court, CA

Suspect Injury

Pleading Phase

McKelvey

15-Apr

US District Court, OR

Wrongful Death

Pleading Phase

In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below:

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Mitchell

12-Apr

US District Court, ED MI

Wrongful Death

Notice of Appeal filed August 2014

Cases that were dismissed or judgment entered during the first quarter of 2015 and through the filing date of this Quarterly Report on Form 10-Q are listed in the table below. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table.

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Juran

10-Dec

Hennepin County District Court, 4th Judicial District, MN

Officer Injury

Dismissed

Miller

13-Jan

New Castle County Superior Court, DE

Wrongful Death

Dismissed

Rascom

14-Apr

US District Court, AZ

Wrongful Death

Dismissed

Thomas (Pikes)

8-Oct

US District Court, WD LA

Wrongful Death

Dismissed

The claims, and in some instances the defense, of each of these lawsuits have been submitted to the Company’s insurance carriers that maintained insurance coverage during the applicable periods. The Company continues to maintain product liability insurance coverage with varying limits and deductibles. The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions).

Policy Year

Policy

Policy

Insurance

Deductible

Defense

Remaining

Active Cases and Cases on

Start

End

Coverage

Amount

Costs

Insurance

Appeal

Date

Date

Covered

Coverage

2004

12/1/03

12/1/04

$

2

$

0.1

N

$

2

n/a

2005

12/1/04

12/1/05

10

0.3

Y

7

n/a

2006

12/1/05

12/1/06

10

0.3

Y

3.7

n/a

2007

12/1/06

12/1/07

10

0.3

Y

8

n/a

2008

12/1/07

12/15/08

10

0.5

Y

—

Koon

2009

12/15/08

12/15/09

10

1

N

10

Derbyshire

2010

12/15/09

12/15/10

10

1

N

10

Thompson, Shymko, Doan

2011

12/15/10

12/15/11

10

1

N

10

n/a

Jan-Jun 2012

12/15/11

6/25/12

7

1

N

7

Ramsey, Mitchell, Firman, Ricks

Jul-Dec 2012

6/25/12

12/15/12

12

1

N

12

n/a

2013

12/15/12

12/15/13

12

1

N

12

n/a

2014

12/15/13

12/15/14

11

4

N

11

Schrock, Moore

2015

12/15/14

12/15/15

10

5

N

10

Jones, McKelvey

Other Litigation

None.

General

From time to time, the Company is notified that it may be a party to a lawsuit or that a claim is being made against it. It is the Company’s policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on the Company. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against the Company. In certain legal matters, we record a liability when losses are deemed probable and reasonably estimable. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, and the severity of any potential loss. We reevaluate and update our accruals as matters progress over time.

Based on our assessment of outstanding litigation and claims as of March 31, 2015, the Company has determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Deferred Tax Assets
	Net deferred income tax assets at March 31, 2015, include capitalized research and development costs, research and development tax credits, non-qualified stock-based compensation expense, deferred warranty revenue, warranty and inventory reserves, accrued vacation, and other items, partially offset by accelerated depreciation expense. The Company’s total current and long-term net deferred tax assets at March 31, 2015 are $16.7 million.
	In preparing the Company’s condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating the Company’s ability to recover its deferred income tax assets, management considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining its provisions for income taxes, its deferred tax assets and liabilities, and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred tax assets.
	Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business. As of each reporting date, management considers new evidence, both positive and negative, that could impact management’s view with regards to future realization of deferred tax assets. As of March 31, 2015, the Company continues to demonstrate three-year cumulative pre-tax income in the U.S. federal and Arizona tax jurisdictions; however, the Arizona R&D Tax Credits start to expire in 2018 with a significant tranche with a gross value of $1.2 million expiring if not used by the end of 2019. Under the Company’s new tax structure, it appears that long term investments which impact short term profits will likely result in some of the R&D credits expiring before they are utilized. Therefore, management has concluded that it is more likely than not that a portion of the Company’s deferred tax assets will not be realized.
	The Company has completed research and development (“R&D”) tax credit studies which identified approximately $10.5 million in tax credits for federal, Arizona and California income tax purposes related to the 2003 through 2015 tax years. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $3.2 million as of March 31, 2015. In addition, management accrued approximately $0.2 million for estimated uncertain tax positions related to certain state income tax liabilities. The Company is currently under an IRS audit for the tax year 2012, and as of March 31, 2015, management believes it is reasonably possible that the amount of unrecognized tax benefits may decrease by as much as $0.5 million in the next 12 months.  Should the total unrecognized tax benefit of $3.4 million be recognized, the Company’s effective tax rate would be favorably impacted. Approximately $1.7 million of the unrecognized tax benefit associated with research and development credits has been netted against the research and development credit deferred tax asset.
	Effective Tax Rate
	The Company’s overall effective tax rate for the three months ended March, 2015, after discrete period adjustments, was 32.6%. Before discrete adjustments the tax rate was 32.9%, which is below the statutory rate primarily due to the impact of the domestic production activities deduction, as well as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, but also increased by the impact of state taxes and non-deductible expenses for items such as ISO stock option expense, meals and entertainment, and lobbying fees. The Company has nearly completed the full implementation of its new international structure, which is new for 2015.  In accounting for the income tax effects of this new structure, the Company has recognized income tax expense in the current quarter based on the results it expects for the full year.  Actual results could be different, impacting the Company’s income tax expense in future quarters.  The Company has chosen this method, from among those available to it, because of its expectation that it will produce the least amount of variability during the year.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity
	Stock Option Activity
	In May 2013, the Company’s stockholders approved a new stock incentive plan authorizing an additional 1.6 million shares, plus remaining available shares under a prior plan for issuance under the new plan. Combined with the legacy stock incentive plans, there are approximately 1.4 million shares available for grant as of March 31, 2015.
	Performance-based stock awards
	The Company has issued performance-based stock options and performance-based RSUs, the vesting of which is contingent upon the achievement of certain performance criteria related to the operating performance of the Company as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the implicit service period (the longer of the period the performance condition is expected to be achieved or the required service period) based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date.
	Restricted Stock Units
	The following table summarizes RSU activity for the three months ended March 31, 2015 (number of units and aggregate intrinsic value in thousands):
		Number		Weighted			Aggregated
		of		Average			Intrinsic Value
		Units		Grant-Date
				Fair Value
	Units outstanding, beginning of year	1,226		$	13.23
	Granted	295		26.75
	Released	(249	)	10.83
	Forfeited	(23	)	12.84
	Units outstanding, end of period	1,249		16.91			$	30,104
	Aggregate intrinsic value represents the Company’s closing stock price on the last trading day of the period, which was $24.11 per share, multiplied by the number of restricted stock units outstanding. As of March 31, 2015, there was $17.5 million in unrecognized compensation costs related to RSUs under the Company's stock plans. The Company expects to recognize the cost related to the RSUs over a weighted average period of 2.98 years. RSUs are released when vesting requirements are met.
	In the three months ended March 31, 2015, the Company granted approximately 36,101 performance-based RSUs, which are included in the table above. As of March 31, 2015, the performance criteria has not been met for any of the 0.1 million performance-based RSUs outstanding. Certain of the performance-based RSUs granted in 2015 and 2014 contain provisions whereby the amount of RSUs that ultimately vest is dependent upon the level of achievement of performance metrics. The amount of RSUs included in the table above related to such grants is the target level, which is the Company's best estimate of the amount of RSUs that will vest. The maximum additional number of RSUs that could be earned is approximately 0.1 million, which are not included in the table above.
	Certain RSUs that vested in the three months ended March 31, 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld were approximately 7,552 and had a value of approximately $0.2 million on their respective vesting dates as determined by the Company’s closing stock price. Payments for the employees’ tax obligations are reflected as a financing activity within the statement of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the amount of shares that would have otherwise been issued as a result of the vesting.
	Stock Option Activity
	The following table summarizes stock option activity for the three months ended March 31, 2015 (number of units and aggregate intrinsic value in thousands):
		Number		Weighted			Weighted Average Remaining Contractual Life (years)		Aggregated
		of		Average					Intrinsic Value
		Options		Exercise
				Price
	Options outstanding, beginning of year	1,641		$	5.26
	Granted	—		—
	Exercised	(107	)	5.65
	Expired / terminated (a)	—		5.52
	Options outstanding, end of period	1,534		5.23			4.25		$	28,962
	Options exercisable, end of period	1,500		5.24			4.26		28,311
	Options expected to vest, end of period	28		4.74			3.73		539
	(a) Actual units terminated during the period was 251, which displayed as zero due to rounding.
	Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock of $24.11 on March 31, 2015. The intrinsic value of options exercised for the three months ended March 31, 2015 and 2014 was $2.1 million and $12.6 million, respectively. As of March 31, 2015, total unrecognized stock-based compensation expense related to unvested stock options was approximately $12,065, which is expected to be recognized over a remaining weighted average period of approximately nine months. Options expected to vest are presented net of forfeitures. As of March 31, 2015, total options outstanding includes approximately 0.3 million performance-based stock options, of which approximately 30,600 were unvested and 25,000 are expected to vest, and the Company expects to recognize $7,000 of expense related to these performance-based stock options over a remaining period of nine months.
	Stock-based Compensation Expense
	When granted, the Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing valuation model, which incorporates various assumptions including volatility, expected life and risk-free interest rates. No options were awarded during the three months ended March 31, 2015 or 2014. The estimated fair value of stock-based compensation awards is amortized to expense on a straight-line basis over the service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested.
		Three Months Ended March 31,
		2015			2014
	Cost of products sold and services delivered	$	70		$	22
	Sales, general and administrative expenses	934			711
	Research and development expenses	540			444
	Total stock-based compensation	$	1,544		$	1,177
	Total stock-based compensation expense recognized in the statements of operations for the three months ended March 31, 2015 and 2014 includes $48,000 and $8,000, respectively, related to ISOs for which no tax benefit is recognized.
	Stock Repurchase Plan
	In May 2014, the Company announced that TASER’s Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. There were no stock repurchase transactions during the quarter ended March 31, 2015. As of March 31, 2015, $7.6 million remains available under the plan for future purchases.

Line_of_Credit

Line of Credit	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Line of Credit	Line of Credit
	The Company has a $10.0 million revolving line of credit with a domestic bank. At March 31, 2015 and December 31, 2014, there were no borrowings under the line. As of March 31, 2015, the Company had letters of credit outstanding of approximately $7,000 under the facility and available borrowing of approximately $10.0 million. The line is secured by substantially all of the assets of the Company, and bears interest at varying rates (currently LIBOR plus 1.5% or Prime less 0.75%). The line of credit matures on July 31, 2016, and requires monthly payments of interest only. The Company’s agreement with the bank requires it to comply with certain financial and other covenants including maintenance of a maximum leverage ratio and minimum fixed charge coverage ratio. The leverage ratio (ratio of total liabilities to tangible net worth) can be no greater than 1:1, and the fixed charge coverage ratio can be no less than 1.25:1, based upon a trailing twelve-month period. At March 31, 2015, the Company’s tangible net worth ratio was 0.41:1 and its fixed charge coverage ratio was 2.80:1. Accordingly, the Company was in compliance with these covenants.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	The Company engages Dr. Mark Kroll, a member of the Board of Directors, to provide consulting services. The expenses related to these services were approximately $41,000 and $31,000 for the three months ended March 31, 2015 and 2014, respectively. At March 31, 2015 and December 31, 2014, the Company had accrued liabilities of approximately $21,000 and $8,000, respectively, related to these services.

Employee_Benefit_Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans
	The Company has a defined contribution profit sharing 401(k) plan for eligible employees, which is qualified under Sections 401(a) and 401(k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum allowed by law of their eligible compensation.
	The Company also has a non-qualified deferred compensation plan for certain executives, key employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from the Company. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for (i) matching and discretionary employer contributions and (ii) the deferral of vested RSU awards. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and the Company does not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the condensed consolidated balance sheets. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of the Company’s general creditors.
	Contributions to the plans are made by both the employee and the Company. Company contributions are based on the level of employee contributions and are immediately vested. The Company’s matching contributions to the plan for the three months ended March 31, 2015 and 2014, were approximately $0.4 million and $0.2 million, respectively. The Company expects to make contributions to the non-qualified deferred compensation plan related to the three months ended March 31, 2015, of approximately $16,000. Future matching or profit sharing contributions to the plans are at the Company’s sole discretion.

Segment_Data

Segment Data	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Data	Segment Data
	The Company’s operations are comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business, which includes the TASER Cam, AXON video products and EVIDENCE.com (the “AXON” segment). The Company includes only revenues and costs directly attributable to the AXON segment in that segment. Included in AXON segment costs are: costs of sales for both products and services, overhead allocation based on direct labor, selling expense for the video sales team, video product management expenses, video trade shows and related expenses, and research and development for products included in the AXON segment. All other costs are included in the TASER Weapons segment. The CODM does not review assets by segment as part of the financial information provided; therefore, no asset information is provided in the following tables.
	Information relative to the Company’s reportable segments is as follows (in thousands):
		Three Months Ended March 31, 2015							Three Months Ended March 31, 2014
		TASER		AXON			Total		TASER		AXON			Total
		Weapons							Weapons
	Product sales	$	38,341	$	4,502		$	42,843	$	32,475	$	3,038		$	35,513
	Service revenue	—		1,919			1,919		—		672			672
	Net sales	38,341		6,421			44,762		32,475		3,710			36,185
	Cost of products sold	11,081		3,148			14,229		10,918		2,656			13,574
	Cost of services delivered	—		665			665		—		403			403
	Gross margin	27,260		2,608			29,868		21,557		651			22,208
	Sales, general and administrative	10,705		3,860			14,565		11,289		2,457			13,746
	Research and development	1,190		3,368			4,558		817		2,789			3,606
	Income (loss) from operations	$	15,365	$	(4,620	)	$	10,745	$	9,451	$	(4,595	)	$	4,856
	Purchase of property and equipment	$	347	$	77		$	424	$	697	$	102		$	799
	Purchase of intangible assets	46		4			50		67		—			67
	Depreciation and amortization	530		87			617		1,078		84			1,162

Subsequent_Events_Subsequent_E

Subsequent Events Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event
	On May 5, 2015, the Company entered into a definitive agreement wherein the Company will acquire all of the outstanding capital stock of MediaSolv Solutions Corporation (“MediaSolv”), a Delaware corporation. MediaSolv provides digital evidence management solutions to law enforcement agencies that allows for multiple sources of evidence to be digitized, stored, searched, retrieved and viewed within a single digital library. The acquisition will allow the Company to leverage MediaSolv’s existing technologies and relationships to further strengthen its position in the market. The acquisition will be accounted for in the second quarter of fiscal 2015 using the acquisition method in accordance with ASC 805, Business Combinations. Accordingly, the identifiable assets acquired and liabilities assumed shall be measured at their acquisition-date fair value. Operating results will be included in the Company’s consolidated financial statements from the effective date of the acquisition.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates
	These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:
	•	product warranty reserves,
	•	inventory valuation reserves,
	•	accounts receivable reserves,
	•	revenue recognition allocated in multiple-deliverable contracts or arrangements,
	•	valuation of goodwill, intangibles and long-lived assets,
	•	recognition, measurement and valuation of current and deferred income taxes,
	•	projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense,
	•	fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and
	•	recognition and measurement of contingencies and accrued litigation expense.
	Actual results could differ materially from those estimates.
Segment and Geographic Information	b. Segment Information
	The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, AXON camera products and EVIDENCE.com (the “AXON” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13.
	c. Geographic Information and Major Customers
	For the three months ended March 31, 2015 and 2014, net sales by geographic area were as follows (in thousands):
		Three Months Ended March 31,
		2015						2014
	United States	$	35,501		79.3	%		$	25,576	70.7	%
	Other Countries	9,261			20.7			10,609		29.3
	Total	$	44,762		100	%		$	36,185	100	%
	Sales to customers outside of the U.S. are typically denominated in U.S. dollars and are attributed to each country based on the shipping address of the distributor or customer. For the three months ended March 31, 2015 or 2014, no individual country outside the U.S. represented more than 10% of net sales. Sales in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of the Company's customers.
	The Company sells its products primarily through a network of unaffiliated distributors. The Company also reserves the right to sell directly to the end user to secure the customer’s account. For the three months ended March 31, 2015 and 2014, no customer represented more than 10% of total net sales. At March 31, 2015 and December 31, 2014, the Company had a trade receivable from one unaffiliated customer comprising 10.1% and 13.4%, respectively, of the aggregate accounts receivable balance.
Income per Common Share	Income per Common Share
	Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):
		Three Months Ended March 31,
		2015			2014
	Numerator for basic and diluted earnings per share:
	Net income	$	7,205		$	3,391
	Denominator:
	Weighted average shares outstanding—basic	53,167			53,190
	Dilutive effect of stock-based awards	1,346			1,934
	Diluted weighted average shares outstanding	54,513			55,124
	Anti-dilutive stock-based awards excluded	362			315
	Net income per common share:
	Basic	$	0.14		$	0.06
	Diluted	$	0.13		$	0.06
Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable	Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable
	The Company derives revenue from two primary sources: (1) the sale of physical products, including our CEWs, AXON cameras, corresponding extended warranties, and related accessories such as cartridges and batteries, and (2) subscription to the Company's EVIDENCE.com SaaS (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract.
	Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price.
	The Company offers the right to purchase extended warranties that include additional services and coverage beyond the limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years.
	EVIDENCE.com and AXON cameras are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of EVIDENCE.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. AXON equipment has stand-alone value and represents a deliverable that is provided to the customer at the time of sale, while EVIDENCE.com services are provided over the specified term of the contract. The Company recognizes revenue for the AXON equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for EVIDENCE.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with EVIDENCE.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the allocation of arrangement consideration, part of the revenue for the equipment may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner.
	In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period.
	The Company recently launched the Officer Safety Plan (“OSP”) whereby a customer enters into a 5 year EVIDENCE.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of the AXON devices every 2.5 years, and includes a TASER CEW device at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the AXON and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of AXON devices at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered.
	Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training revenue is recorded as the service is provided.
	Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about of the Company’s deferred revenue.
	Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates and is based on their judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions.
	The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes. There were no outstanding balances related to such arrangements as of March 31, 2015 or December 31, 2014.
Standard Warranties	Standard Warranties
	The Company warranties its CEWs, AXON cameras and E-Docks from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets.
	Changes in the Company’s estimated product warranty liabilities are as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance, beginning of period	$	675		$	955
	Utilization of accrual	(118		)	(174		)
	Warranty (recovery) expense	(34		)	306
	Balance, end of period	$	523		$	1,087
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:
	•	Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.
	•	Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.
	•	Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability.
	The Company has cash equivalents and investments, which at March 31, 2015 and December 31, 2014, were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of March 31, 2015 and December 31, 2014 was $1.5 million and $1.1 million, respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique.
	The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets.
Valuation of Goodwill, Intangibles and Long-lived Assets	Valuation of Goodwill, Intangibles and Long-lived Assets
	Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (i) prospectively to all awards granted or modified after the effective date; or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, ASU 2014-09 provides for the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification Topic No. 605, “Revenue Recognition,” most industry-specific guidance throughout the industry topics of the Accounting Standards Codification, and some cost guidance related to construction-type and production-type contracts. ASU 2014-09 is effective for public entities for annual periods and interim periods within those annual periods beginning after December 15, 2016. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation
	Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Net Sales by Geographic Area	For the three months ended March 31, 2015 and 2014, net sales by geographic area were as follows (in thousands):
		Three Months Ended March 31,
		2015						2014
	United States	$	35,501		79.3	%		$	25,576	70.7	%
	Other Countries	9,261			20.7			10,609		29.3
	Total	$	44,762		100	%		$	36,185	100	%
Weighted Average Number of Shares Outstanding and Income Per Share	The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data):
		Three Months Ended March 31,
		2015			2014
	Numerator for basic and diluted earnings per share:
	Net income	$	7,205		$	3,391
	Denominator:
	Weighted average shares outstanding—basic	53,167			53,190
	Dilutive effect of stock-based awards	1,346			1,934
	Diluted weighted average shares outstanding	54,513			55,124
	Anti-dilutive stock-based awards excluded	362			315
	Net income per common share:
	Basic	$	0.14		$	0.06
	Diluted	$	0.13		$	0.06
Summary of Changes in Estimated Product Warranty Liabilities	Changes in the Company’s estimated product warranty liabilities are as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Balance, beginning of period	$	675		$	955
	Utilization of accrual	(118		)	(174		)
	Warranty (recovery) expense	(34		)	306
	Balance, end of period	$	523		$	1,087

Cash_Cash_Equivalents_and_Inve1

Cash, Cash Equivalents and Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type	The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at March 31, 2015 and December 31, 2014 (in thousands):
		As of March 31, 2015
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-Term Investments		Long-Term Investments
	Cash	$	44,113	$	—	$	—		$	44,113	$	44,113	$	—	$	—
	Level 1:
	Money market funds	2,054		—		—			2,054		2,054		—		—
	Corporate bonds	36,548		—		(54		)	36,494		—		26,162		10,386
	Subtotal	38,602		—		(54		)	38,548		2,054		26,162		10,386
	Level 2:
	State and municipal obligations	19,108		13		—			19,121		681		15,580		2,847
	Certificates of deposit	2,950		—		—			2,950		—		1,470		1,480
	Subtotal	22,058		13		—			22,071		681		17,050		4,327
	Total	$	104,773	$	13	$	(54	)	$	104,732	$	46,848	$	43,212	$	14,713
		As of December 31, 2014
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Cash and Cash Equivalents		Short-Term Investments		Long-Term Investments
	Cash	$	44,260	$	—	$	—		$	44,260	$	44,260	$	—	$	—
	Level 1:
	Money market funds	3,932		—		—			3,932		3,932		—		—
	Corporate bonds	20,388		—		(34		)	20,354		—		15,656		4,732
	Subtotal	24,320		—		(34		)	24,286		3,932		15,656		4,732
	Level 2:
	State and municipal obligations	19,145		18		—			19,163		175		15,891		3,079
	Certificates of deposit	2,712		—		—			2,712		—		1,227		1,485
	Subtotal	21,857		18		—			21,875		175		17,118		4,564
	Total	$	90,437	$	18	$	(34	)	$	90,421	$	48,367	$	32,774	$	9,296
Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at March 31, 2015 by contractual maturity (in thousands):
		Amortized Cost		Fair Value
	Due in less than one year	$	43,212	$	43,190
	Due after one year, through two years	14,713		14,694
	Due after two years	—		—
	Total short-term and long-term investments	$	57,925	$	57,884

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015			2014
	Raw materials	$	13,678		$	12,229
	Work-in-process	128			111
	Finished goods	10,416			7,337
	Reserve for excess and obsolete inventory	(1,596		)	(1,354		)
	Total inventory	$	22,626		$	18,323

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Other than goodwill	Intangible assets (other than goodwill) consisted of the following (in thousands):
				March 31, 2015							December 31, 2014
		Useful		Gross		Accumulated			Net		Gross		Accumulated			Net
		Life		Carrying		Amortization			Carrying		Carrying		Amortization			Carrying
				Amount					Amount		Amount					Amount
	Amortized:
	Domain names	5 years		$	125	$	(117	)	$	8	$	125	$	(114	)	$	11
	Issued patents	4-15 years		1,799		(584		)	1,215		1,759		(549		)	1,210
	Issued trademarks	9-11 years		575		(211		)	364		566		(205		)	361
	Total amortized			2,499		(912		)	1,587		2,450		(868		)	1,582
	Not amortized:
	TASER trademark			900					900		900					900
	Patents and trademarks pending			478					478		633					633
	Total not amortized			1,378					1,378		1,533					1,533
	Total intangible assets			$	3,877	$	(912	)	$	2,965	$	3,983	$	(868	)	$	3,115
Estimated Amortization Expense of Intangible Assets	Estimated amortization for intangible assets with definitive lives for the remaining nine months of 2015, the next five years ended December 31, and thereafter, is as follows (in thousands):
	2015 (remaining nine months)	$	136
	2016	176
	2017	172
	2018	162
	2019	152
	2020	282
	Thereafter	507
	Total	$	1,587

Deferred_Revenue_Tables

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Revenue Disclosure [Abstract]
Summary of Deferred Revenue	Deferred revenue consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015		2014
	Warranty	$	21,701	$	21,973
	AXON services	9,055		9,286
	Hardware equipment	5,988		4,252
	Other	327		177
	Total deferred revenue	37,071		35,688
	Total current portion of deferred revenue	14,628		14,020
	Total long-term portion of deferred revenue	$	22,443	$	21,668

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):
		2015		2014
	Accrued salaries and benefits	$	2,144	$	3,699
	Accrued judgments and settlements	80		108
	Accrued professional fees	204		257
	Accrued warranty expense	523		675
	Accrued income and other taxes	1,893		539
	Other accrued expenses	2,155		3,967
	Accrued liabilities	$	6,999	$	9,245

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Loss Contingencies

With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter.

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Koon

8-Dec

17th Judicial Circuit Court, Broward County, FL

Training Injury

Discovery Phase

Derbyshire

9-Nov

Ontario, Canada Superior Court of Justice

Officer Injury

Discovery Phase

Thompson

10-Mar

11th Judicial Circuit Court, Miami-Dade County, FL

Suspect Injury During Arrest

Pleading Phase

Doan

10-Apr

The Queen's Bench Alberta, Red Deer Judicial Dist.

Wrongful Death

Discovery Phase

Shymko

10-Dec

The Queen's Bench, Winnipeg Centre, Manitoba

Wrongful Death

Pleading Phase

Ramsey

12-Jan

17th Judicial Circuit Court, Broward County, FL

Wrongful Death

Discovery Phase

Firman

12-Apr

Ontario, Canada Superior Court of Justice

Wrongful Death

Pleading Phase

Ricks

12-May

US District Court, WD LA

Wrongful Death

Motion Phase, trial scheduled June 2015

Schrock

14-Sep

San Bernardino County Superior Court, CA

Wrongful Death

Pleading Phase

Moore

14-Nov

St. Louis County Circuit Court, MO

Wrongful Death

Pleading Phase

Jones

15-Jan

Los Angeles County Superior Court, CA

Suspect Injury

Pleading Phase

McKelvey

15-Apr

US District Court, OR

Wrongful Death

Pleading Phase

Summary of Other Product Litigation Matters

In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below:

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Mitchell

12-Apr

US District Court, ED MI

Wrongful Death

Notice of Appeal filed August 2014

Summary of Cases Dismissed or Judgment Entered

Plaintiff

Month

Jurisdiction

Claim Type

Status

Served

Juran

10-Dec

Hennepin County District Court, 4th Judicial District, MN

Officer Injury

Dismissed

Miller

13-Jan

New Castle County Superior Court, DE

Wrongful Death

Dismissed

Rascom

14-Apr

US District Court, AZ

Wrongful Death

Dismissed

Thomas (Pikes)

8-Oct

US District Court, WD LA

Wrongful Death

Dismissed

Information Regarding the Company's Insurance Coverage

The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions).

Policy Year

Policy

Policy

Insurance

Deductible

Defense

Remaining

Active Cases and Cases on

Start

End

Coverage

Amount

Costs

Insurance

Appeal

Date

Date

Covered

Coverage

2004

12/1/03

12/1/04

$

2

$

0.1

N

$

2

n/a

2005

12/1/04

12/1/05

10

0.3

Y

7

n/a

2006

12/1/05

12/1/06

10

0.3

Y

3.7

n/a

2007

12/1/06

12/1/07

10

0.3

Y

8

n/a

2008

12/1/07

12/15/08

10

0.5

Y

—

Koon

2009

12/15/08

12/15/09

10

1

N

10

Derbyshire

2010

12/15/09

12/15/10

10

1

N

10

Thompson, Shymko, Doan

2011

12/15/10

12/15/11

10

1

N

10

n/a

Jan-Jun 2012

12/15/11

6/25/12

7

1

N

7

Ramsey, Mitchell, Firman, Ricks

Jul-Dec 2012

6/25/12

12/15/12

12

1

N

12

n/a

2013

12/15/12

12/15/13

12

1

N

12

n/a

2014

12/15/13

12/15/14

11

4

N

11

Schrock, Moore

2015

12/15/14

12/15/15

10

5

N

10

Jones, McKelvey

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Restricted Stock Unit Activity	The following table summarizes RSU activity for the three months ended March 31, 2015 (number of units and aggregate intrinsic value in thousands):
		Number		Weighted			Aggregated
		of		Average			Intrinsic Value
		Units		Grant-Date
				Fair Value
	Units outstanding, beginning of year	1,226		$	13.23
	Granted	295		26.75
	Released	(249	)	10.83
	Forfeited	(23	)	12.84
	Units outstanding, end of period	1,249		16.91			$	30,104
Summary of the Company's Stock Options Activity	The following table summarizes stock option activity for the three months ended March 31, 2015 (number of units and aggregate intrinsic value in thousands):
		Number		Weighted			Weighted Average Remaining Contractual Life (years)		Aggregated
		of		Average					Intrinsic Value
		Options		Exercise
				Price
	Options outstanding, beginning of year	1,641		$	5.26
	Granted	—		—
	Exercised	(107	)	5.65
	Expired / terminated (a)	—		5.52
	Options outstanding, end of period	1,534		5.23			4.25		$	28,962
	Options exercisable, end of period	1,500		5.24			4.26		28,311
	Options expected to vest, end of period	28		4.74			3.73		539
	(a) Actual units terminated during the period was 251, which displayed as zero due to rounding.
Reported Share-Based Compensation	The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested.
		Three Months Ended March 31,
		2015			2014
	Cost of products sold and services delivered	$	70		$	22
	Sales, general and administrative expenses	934			711
	Research and development expenses	540			444
	Total stock-based compensation	$	1,544		$	1,177

Segment_Data_Tables

Segment Data (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Summary of Operational Information Relative to the Company's Reportable Segments	Information relative to the Company’s reportable segments is as follows (in thousands):
		Three Months Ended March 31, 2015							Three Months Ended March 31, 2014
		TASER		AXON			Total		TASER		AXON			Total
		Weapons							Weapons
	Product sales	$	38,341	$	4,502		$	42,843	$	32,475	$	3,038		$	35,513
	Service revenue	—		1,919			1,919		—		672			672
	Net sales	38,341		6,421			44,762		32,475		3,710			36,185
	Cost of products sold	11,081		3,148			14,229		10,918		2,656			13,574
	Cost of services delivered	—		665			665		—		403			403
	Gross margin	27,260		2,608			29,868		21,557		651			22,208
	Sales, general and administrative	10,705		3,860			14,565		11,289		2,457			13,746
	Research and development	1,190		3,368			4,558		817		2,789			3,606
	Income (loss) from operations	$	15,365	$	(4,620	)	$	10,745	$	9,451	$	(4,595	)	$	4,856
	Purchase of property and equipment	$	347	$	77		$	424	$	697	$	102		$	799
	Purchase of intangible assets	46		4			50		67		—			67
	Depreciation and amortization	530		87			617		1,078		84			1,162

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Source		Distributor
	Distributor
Summary Of Significant Accounting Policy [Line Items]
Number Of Distributers	1		1
Accounts and notes receivable by customers one	10.10%		13.40%
Number of revenue sources	2
Company receive payment	30 days
Warranty period	1 year
Corporate owned life insurance policies fair value	$1.50		$1.10
Goodwill and intangible asset impairment	$0.10	$0.10
Extended Product Warranty | Minimum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	1 year
Extended Product Warranty | Maximum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	5 years
Evidence. Com
Summary Of Significant Accounting Policy [Line Items]
Subscription period	5 years
Device upgrade period	2 years 6 months

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Net Sales by Geographic Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$44,762	$36,185
Percentage of Net sales by Geographic Area	100.00%	100.00%
United States
Segment Reporting Information [Line Items]
Net sales by Geographic Area	35,501	25,576
Percentage of Net sales by Geographic Area	79.30%	70.70%
Other Countries
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$9,261	$10,609
Percentage of Net sales by Geographic Area	20.70%	29.30%

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator for basic and diluted earnings per share:
Net income	$7,205	$3,391
Denominator:
Weighted average shares outstanding—basic	53,167	53,190
Dilutive effect of stock-based awards (in shares)	1,346	1,934
Diluted weighted average shares outstanding	54,513	55,124
Anti-dilutive stock-based awards excluded	362	315
Net income (loss) per common share:
Basic (in dollars per share)	$0.14	$0.06
Diluted (in dollars per share)	$0.13	$0.06

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance, beginning of period	$675	$955
Utilization of accrual	-118	-174
Warranty (recovery) expense	-34	306
Balance, end of period	$523	$1,087

Cash_Cash_Equivalents_and_Inve2

Cash, Cash Equivalents, and Investments - Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$104,773	$90,437
Gross Unrealized Gains	13	18
Gross Unrealized Losses	-54	-34
Fair Value	104,732	90,421
Cash Cash Equivalent And Investments Amortized Cost	46,848	48,367
Short-term investments	43,212	32,774
Long-term investments	14,713	9,296
State and Municipal Obligations
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	19,108	19,145
Gross Unrealized Gains	13	18
Gross Unrealized Losses	0	0
Fair Value	19,121	19,163
Cash Cash Equivalent And Investments Amortized Cost	681	175
Short-term investments	15,580	15,891
Long-term investments	2,847	3,079
Certificates of Deposit
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	2,950	2,712
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	2,950	2,712
Cash Cash Equivalent And Investments Amortized Cost	0	0
Short-term investments	1,470	1,227
Long-term investments	1,480	1,485
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	38,602	24,320
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-54	-34
Fair Value	38,548	24,286
Cash Cash Equivalent And Investments Amortized Cost	2,054	3,932
Short-term investments	26,162	15,656
Long-term investments	10,386	4,732
Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	22,058	21,857
Gross Unrealized Gains	13	18
Gross Unrealized Losses	0	0
Fair Value	22,071	21,875
Cash Cash Equivalent And Investments Amortized Cost	681	175
Short-term investments	17,050	17,118
Long-term investments	4,327	4,564
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	44,113	44,260
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	44,113	44,260
Cash Cash Equivalent And Investments Amortized Cost	44,113	44,260
Short-term investments	0	0
Long-term investments	0	0
Money Market Funds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	2,054	3,932
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	2,054	3,932
Cash Cash Equivalent And Investments Amortized Cost	2,054	3,932
Short-term investments	0	0
Long-term investments	0	0
Corporate Bonds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	36,548	20,388
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-54	-34
Fair Value	36,494	20,354
Cash Cash Equivalent And Investments Amortized Cost	0	0
Short-term investments	26,162	15,656
Long-term investments	$10,386	$4,732

Cash_Cash_Equivalents_and_Inve3

Cash, Cash Equivalents, and Investments - Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	$43,212	$32,774
Due after one year, through two years	14,713	9,296
Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	43,212
Due after one year, through two years	14,713
Due after two years	0
Total short-term and long-term investments	57,925
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	43,190
Due after one year, through two years	14,694
Due after two years	0
Total short-term and long-term investments	$57,884

Inventory_Detail

Inventory (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$13,678	$12,229
Work-in-process	128	111
Finished goods	10,416	7,337
Reserve for excess and obsolete inventory	-1,596	-1,354
Total inventory	$22,626	$18,323

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Goodwill [Line Items]
Goodwill	$2,206		$2,206
Amortization expense	61	40
Familiar Inc
Goodwill [Line Items]
Goodwill	$2,206		$2,206

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Intangible Assets Other than Goodwill (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$2,499		$2,450
Accumulated amortization	-912		-868
Total	1,587		1,582
Not amortized intangible assets, carrying amount	1,378		1,533
Intangible assets, gross carrying amount	3,877		3,983
Intangible assets, net carrying amount	2,965	3,115	3,115
TASER trademark
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	900		900
Patents and trademarks pending
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	478		633
Domain names
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	5 years
Amortized intangible assets, gross carrying amount	125		125
Accumulated amortization	-117		-114
Total	8		11
Issued patents
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	1,799		1,759
Accumulated amortization	-584		-549
Total	1,215		1,210
Issued patents | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Issued patents | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	15 years
Issued trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	575		566
Accumulated amortization	-211		-205
Total	$364		$361
Issued trademarks | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	9 years
Issued trademarks | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	11 years

Recovered_Sheet1

Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Mar. 31, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (remaining nine months)	$136
2016	176
2017	172
2018	162
2019	152
2020	282
Thereafter	507
Total	$1,587	$1,582

Deferred_Revenue_Summary_of_De

Deferred Revenue - Summary of Deferred Revenue (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$37,071	$35,688
Current portion of deferred revenue	14,628	14,020
Deferred revenue, net of current portion	22,443	21,668
Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	21,701	21,973
Current portion of deferred revenue	7,300
AXON services
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	9,055	9,286
Current portion of deferred revenue	5,500
Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	5,988	4,252
Current portion of deferred revenue	1,600
Other
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$327	$177

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued salaries and benefits	$2,144	$3,699
Accrued judgments and settlements	80	108
Accrued professional fees	204	257
Accrued warranty expense	523	675	1,087	955
Accrued income and other taxes	1,893	539
Other accrued expenses	2,155	3,967
Accrued liabilities	$6,999	$9,245

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Sep. 30, 2011
	Case	Case
	Lawsuit
Commitments and Contingencies Disclosure [Abstract]
Number of lawsuits against Company	12
Number of active product liability cases	12	55

Commitments_and_Contingencies_2

Commitments and Contingencies - Information Regarding the Company's Insurance Coverage (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
2004
Product Liability Contingency [Line Items]
Insurance Coverage	$2
Deductible Amount	0.1
Remaining Insurance Coverage	2
2005
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	7
2006
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	3.7
2007
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	8
2008
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.5
Remaining Insurance Coverage	0
2009
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2010
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2011
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
Jan - Jun 2012
Product Liability Contingency [Line Items]
Insurance Coverage	7
Deductible Amount	1
Remaining Insurance Coverage	7
Jul - Dec 2012
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2013
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2014
Product Liability Contingency [Line Items]
Insurance Coverage	11
Deductible Amount	4
Remaining Insurance Coverage	11
2015
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	5
Remaining Insurance Coverage	$10

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Line Items]
Deferred tax assets, net	$16,700,000
Research and development tax credit studies	10,500,000
Unrecognized tax benefits	3,400,000
Deferred Tax Assets, Valuation Allowance	500,000
Cash paid for income taxes—net	209,000	50,000
Overall effective tax rate, after discrete period adjustments	32.60%
Effective tax rate, before discrete period adjustment	32.90%
Research and Development Credits
Income Tax Disclosure [Line Items]
Tax credit carryforward, valuation allowance	1,700,000
Expiring in 2019
Income Tax Disclosure [Line Items]
Tax Credit Carryforward, Amount	1,200,000
State
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	200,000
Federal
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	$3,200,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	31-May-13	Dec. 31, 2014	31-May-14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option available for future grants	1,400,000
Maximum additional shares to be issued	100,000
Tax payments, for net share settlement of share based award	$194,000	$1,138,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	17,500,000
Weighted average period	2 years 11 months 23 days
Approximate units outstanding	1,248,611	1,226,088
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approximate units of performance restricted stock granted	36,101
Approximate units outstanding	100,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld, for net share settlement of share based award	7,552
Tax payments, for net share settlement of share based award	200,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share	$24.11
Total intrinsic value of options exercised	2,100,000	12,600,000
Number of options outstanding	1,533,828			1,641,083
Non-Vested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	12,065
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	7,000
Number of options outstanding	300,000
Unvested performance options	30,600
Unvested share, expected to vest	25,000
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock option expense	48,000	8,000
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized			1,600,000
2014 Stock Repurchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding common stock repurchase program authorized amount					30,000,000
Remaining authorized repurchase amount	$7,600,000

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) (Restricted Stock, USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year		1,226,088
Number of Units, Granted	294,639
Number of Units, Released	-249,255
Number of Units, Forfeited	-22,861
Number of Units outstanding, end of year	1,248,611	1,226,088
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year		$13.23
Weighted Average Grant Date Fair Value, Granted	$26.75
Weighted Average Grant Date Fair Value, Released	$10.83
Weighted Average Grant Date Fair Value, Forfeited	$12.84
Weighted Average Grant Date Fair Value, Units outstanding, end of year	$16.91	$13.23
Aggregate intrinsic value at year end (in thousands)	$30,104

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of the Company's Stock Options Activity (Detail) (Stock Options, USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Options outstanding, beginning of year	1,641,083
Number of options, Granted	0
Number of options, Exercised	-107,004
Number of options, Expired / terminated	-251
Number of options, Options outstanding, end of year	1,533,828
Number of options, Options exercisable, end of year	1,500,379
Number of options, Options expected to vest, end of year	27,849
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding, beginning of year	$5.26
Weighted average exercise price, Granted	$0
Weighted average exercise price, Exercised	$5.65
Weighted average exercise price, Expired / terminated	$5.52
Weighted average exercise price, Options outstanding, end of year	$5.23
Weighted average exercise price, Options exercisable, end of year	$5.24
Weighted average exercise price, Options expected to vest, end of year	$4.74
Weighted average remaining contractual life, Options outstanding (in years)	4 years 3 months
Weighted average remaining contractual life, Options exercisable (in years)	4 years 3 months 4 days
Weighted average remaining contractual life, Options expected to vest (in years)	3 years 8 months 23 days
Aggregate intrinsic value, Options outstanding	$28,962
Aggregate intrinsic value, Options exercisable	28,311
Aggregate intrinsic value, Options expected to vest	$539

Stockholders_Equity_Reported_S

Stockholders' Equity - Reported Share-Based Compensation (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$1,544	$1,177
Cost of products sold and services delivered
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	70	22
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	934	711
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$540	$444

Line_of_Credit_Additional_Info

Line of Credit - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total availability under line of credit agreement	$10,000,000	$10,000,000
Letters of credit outstanding amount	7,000
Available borrowing under letter of credit	$10,000,000
Varying Interest on Line of credit agreement	LIBOR plus 1.5% or Prime less 0.75%
Maturity date of line of credit	31-Jul-16
Maximum ratio of total liabilities to tangible net worth	1
Minimum required fixed coverage charge ratio	1.25
Period used for calculating ratios	12 months
Company's tangible net worth ratio	0.41
Fixed coverage charge ratio	2.8
Line of Credit | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Line of credit interest rate	1.50%
Line of Credit | Prime Rate
Debt Instrument [Line Items]
Line of credit interest rate	0.75%

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (Consulting Services, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Consulting Services
Related Party Transaction [Line Items]
Transaction expenses incurred by parent company	$41	$31
Outstanding payables due to related party	$21		$8

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Employee deferrals deemed vested percentage upon contribution	100.00%
Company's contributions to the plan	$400,000	$200,000
Company's expected contributions to the plan	$16,000
Minimum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of base salary	80.00%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of other compensation	100.00%

Segment_Data_Additional_Inform

Segment Data - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2
Segment Reporting Information [Line Items]
Product sales	$42,843	$35,513
Service revenue	1,919	672
Net sales	44,762	36,185
Cost of products sold	14,229	13,574
Cost of services delivered	665	403
Gross margin	29,868	22,208
Sales, general and administrative	14,565	13,746
Research and development	4,558	3,606
Income from operations	10,745	4,856
Purchase of property and equipment	424	799
Purchase of intangible assets	50	67
Depreciation and amortization	617	1,162
TASER Weapons
Segment Reporting Information [Line Items]
Product sales	38,341	32,475
Service revenue	0	0
Net sales	38,341	32,475
Cost of products sold	11,081	10,918
Cost of services delivered	0	0
Gross margin	27,260	21,557
Sales, general and administrative	10,705	11,289
Research and development	1,190	817
Income from operations	15,365	9,451
Purchase of property and equipment	347	697
Purchase of intangible assets	46	67
Depreciation and amortization	530	1,078
AXON
Segment Reporting Information [Line Items]
Product sales	4,502	3,038
Service revenue	1,919	672
Net sales	6,421	3,710
Cost of products sold	3,148	2,656
Cost of services delivered	665	403
Gross margin	2,608	651
Sales, general and administrative	3,860	2,457
Research and development	3,368	2,789
Income from operations	-4,620	-4,595
Purchase of property and equipment	77	102
Purchase of intangible assets	4	0
Depreciation and amortization	$87	$84